Cleo DiagnosticsASX:COV -1.98%17 Shareholder Yield % is -6.76% as of Dec. 2025. GuruFocus rates ASX:COV with a GF Score™ of 17/100. The stock has 1 warning sign investors should review. Among 819 Medical Devices & Instruments companies, Cleo Diagnostics ranks worse than 77.05% on this metric.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return.
As of today, Cleo Diagnostics's Shareholder Yield % was -6.76%.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."
Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.
Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.
Cleo Diagnostics Shareholder Yield % Related Terms
Cleo Diagnostics Shareholder Yield % Historical Data
* Premium members only.
The historical data trend for Cleo Diagnostics's Shareholder Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:COV vs ABT, SYK, MDT: Shareholder Yield % Comparison
For the Medical Devices subindustry, Cleo Diagnostics's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cleo Diagnostics Shareholder Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cleo Diagnostics's Shareholder Yield % distribution charts can be found below:
* The bar in red indicates where Cleo Diagnostics's Shareholder Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
Cleo Diagnostics (ASX:COV) has a Shareholder Yield % of -6.76% as of Dec. 2025. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Cleo Diagnostics and its competitors. According to the industry distribution chart, Cleo Diagnostics ranks #631 out of 819 companies in the Medical Devices & Instruments industry, placing it in the top 77%.
Is Cleo Diagnostics' Shareholder Yield % too high?
Cleo Diagnostics' current Shareholder Yield % is -6.76%. Based on the distribution chart, Cleo Diagnostics ranks #631 out of 819 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Cleo Diagnostics has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Cleo Diagnostics' Shareholder Yield % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Cleo Diagnostics ranks #631 out of 819 companies for Shareholder Yield %. This places Cleo Diagnostics in the lower half of its industry. The industry median Shareholder Yield % is 0.17. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Medical Devices & Instruments company?
The median Shareholder Yield % among Medical Devices & Instruments companies is 0.17, based on 819 companies in the industry. Companies in the top quartile (top 25%) have a Shareholder Yield % significantly above this median, while those in the bottom quartile fall well below. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Cleo Diagnostics and its competitors. For the Medical Devices & Instruments industry, the median Shareholder Yield % is 0.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cleo Diagnostics's current Shareholder Yield % is -6.76%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cleo Diagnostics stock overvalued right now?
Cleo Diagnostics (ASX:COV) has a current Shareholder Yield % of -6.76%. The current Shareholder Yield % is -6.76%. Cleo Diagnostics' overall GF Score™ is 17/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Cleo Diagnostics (ASX:COV), the current Shareholder Yield % is -6.76% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cleo Diagnostics Ltd is focused on the development of non-invasive blood-based IVD tests to detect the presence, and recurrence, of ovarian cancer. The company's first product to market is intended to be the Triage Test which results to accurately differentiate patients with malignant ovarian cancer from those with benign gynecological conditions. The company aims to improve the diagnostic process and procedures for detecting ovarian cancer and, in this regard, improve quality-of-life outcomes for patients who have been diagnosed with ovarian cancer.
17GF Score
Get the complete analysis for ASX:COV
Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:COV has been successfully added to your 